Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Unity Biotechnology Inc (UBX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 475,677
  • Shares Outstanding, K 42,323
  • Annual Sales, $ 1,382 K
  • Annual Income, $ -44,656 K
  • 36-Month Beta N/A
  • Price/Sales 344.17
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -5.81
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/20/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.80 +4.07%
on 02/13/19
16.87 -33.37%
on 01/16/19
-5.17 (-31.51%)
since 01/15/19
3-Month
10.80 +4.07%
on 02/13/19
17.46 -35.62%
on 12/27/18
-1.11 (-8.99%)
since 11/15/18

Most Recent Stories

More News
UNITY Biotechnology Expands Ongoing UBX0101 Phase 1 Study to Further Evaluate SASP Factors in Osteoarthritis of the Knee

- Results expected in the second quarter of 2019 -

UBX : 11.24 (-0.09%)
Ascentage Pharma Announces New License with Unity Biotechnology

Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced that Unity Biotechnology, Inc. (Nasdaq:UBX)...

UBX : 11.24 (-0.09%)
Ascentage Pharma Announces New License with Unity Biotechnology

ROCKVILLE, Md. and HONG KONG , Jan. 8, 2019 /PRNewswire/ -- Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers...

UBX : 11.24 (-0.09%)
UNITY Biotechnology Announces Completion of UBX1967 License and Advance into IND-Enabling Studies for Age-Related Diseases of the Eye

UNITY Biotechnology, Inc. ("UNITY") [NASDAQ:UBX], a biotechnology company developing therapeutics to extend human healthspan by slowing, halting or reversing diseases of aging, today announced it has selected...

UBX : 11.24 (-0.09%)
UNITY (UBX) Soars: Stock Adds 5.1% in Session

UNITY (UBX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

UBX : 11.24 (-0.09%)
ALXN : 129.42 (+2.77%)
UNITY Biotechnology, Inc. Appoints Margo Roberts Ph.D. to Board of Directors

UNITY Biotechnology, Inc. ("UNITY") [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced the appointment...

UBX : 11.24 (-0.09%)
UNITY Biotechnology Announces Additional Cohort to Evaluate Higher Dose in Ongoing UBX0101 Phase 1 Study in Osteoarthritis of the Knee

UNITY Biotechnology, Inc. ("UNITY") [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that it will include...

MG.TO : 68.81 (+0.70%)
UBX : 11.24 (-0.09%)
UNITY Biotechnology, Inc. to Host Investor & Analyst Event on Cellular Senescence

- Event will be webcast live -

UBX : 11.24 (-0.09%)
UNITY Biotechnology, Inc. to Announce Third Quarter 2018 Financial Results

UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, plans to report results for the...

UBX : 11.24 (-0.09%)
UNITY Biotechnology, Inc. Announces Closing of Initial Public Offering

UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX) today announced the closing of the Company's initial public offering of 5,000,000 shares of common stock at a public offering price of $17.00 per share,...

MS : 41.99 (+3.12%)
UBX : 11.24 (-0.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

See More Share

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar